The report covers the period ending June 30, 2026, and provides a window into the company’s progress with its flagship ProSense system. This technology utilizes liquid nitrogen to freeze and destroy both benign and cancerous tumors, serving as an alternative to traditional surgical removal for breast, kidney, bone, and lung cancer patients.
In section Releases
IceCure Medical Schedules First-Half 2026 Earnings Call
Caesarea-based IceCure Medical will release its financial and operational results for the first six months of 2026 on August 12. The company, which specializes in minimally invasive cryoablation technology for tumor destruction, plans to host a conference call and webcast to review these figures before the Nasdaq market opens.
Investors can access the conference call at 10:00 a.m. EDT. Dial-in numbers are 1-888-407-2553 for the United States and +972-3-918-0696 for Israel and international participants. A live webcast will be hosted on the Veidan Conferencing platform, with a recording available on the company’s investor relations website following the event.
Comments (0)
No comments yet. Be the first!